| Literature DB >> 25734396 |
G A Abel1, J Shelton2, S Johnson3, L Elliss-Brookes3, G Lyratzopoulos4.
Abstract
BACKGROUND: Although overall sociodemographic and cancer site variation in the risk of cancer diagnosis through emergency presentation has been previously described, relatively little is known about how this risk may vary differentially by sex, age and deprivation group between patients with a given cancer.Entities:
Mesh:
Year: 2015 PMID: 25734396 PMCID: PMC4385986 DOI: 10.1038/bjc.2015.52
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Crude proportion, and crude and adjusted odds ratios for diagnosis through emergency presentation, by age group, sex, deprivation group, year of diagnosis and cancer diagnosis
| All Cases | 749 645 | 232 281 | 31.0% | N/A | N/A |
| 25–34 | 8586 | 1659 | 19.3% | 0.65 (0.62–0.69) | 1.10 (1.00–1.21) |
| 35–44 | 22 356 | 4481 | 20.0% | 0.68 (0.66–0.70) | 1.01 (0.95–1.07) |
| 45–54 | 57 128 | 12 920 | 22.6% | 0.79 (0.78–0.81) | 0.94 (0.90–0.97) |
| 55–64 | 140 074 | 33 741 | 24.1% | 0.86 (0.85–0.87) | 0.91 (0.89–0.93) |
| 65–74 | 208 095 | 56 025 | 26.9% | Reference | Reference |
| 75–84 | 218 951 | 77 723 | 35.5% | 1.49 (1.47–1.51) | 1.47 (1.45–1.50) |
| 85+ | 94 455 | 45 732 | 48.4% | 2.55 (2.51–2.59) | 2.62 (2.56–2.69) |
| Men | 428 155 | 126 300 | 29.5% | Reference | Reference |
| Women | 321 490 | 105 981 | 33.0% | 1.18 (1.16–1.19) | 1.06 (1.04–1.08) |
| 1—Least deprived | 138 269 | 36 255 | 26.2% | Reference | Reference |
| 2 | 155 743 | 44 332 | 28.5% | 1.12 (1.10–1.14) | 1.09 (1.06–1.11) |
| 3 | 157 940 | 48 256 | 30.6% | 1.24 (1.22–1.26) | 1.19 (1.16–1.22) |
| 4 | 152 953 | 50 779 | 33.2% | 1.40 (1.38–1.42) | 1.33 (1.30–1.36) |
| 5—Most deprived | 144 740 | 52 659 | 36.4% | 1.61 (1.58–1.64) | 1.55 (1.51–1.59) |
| 2006 | 146 259 | 47 987 | 32.8% | Reference | Reference |
| 2007 | 147 473 | 46 333 | 31.4% | 0.94 (0.92–0.95) | 0.93 (0.91–0.96) |
| 2008 | 152 125 | 46 784 | 30.8% | 0.91 (0.90–0.92) | 0.91 (0.89–0.93) |
| 2009 | 153 600 | 46 890 | 30.5% | 0.90 (0.89–0.91) | 0.90 (0.88–0.92) |
| 2010 | 150 188 | 44 287 | 29.5% | 0.86 (0.84–0.87) | 0.87 (0.85–0.89) |
| Melanoma | 45 561 | 967 | 2.1% | 0.03 (0.03–0.04) | 0.04 (0.04–0.04) |
| Oral | 9801 | 491 | 5.0% | 0.08 (0.08–0.09) | 0.09 (0.08–0.10) |
| Thyroid | 8254 | 460 | 5.6% | 0.09 (0.09–0.10) | 0.11 (0.10–0.13) |
| Oropharynx | 6429 | 365 | 5.7% | 0.10 (0.09–0.11) | 0.12 (0.10–0.14) |
| Anal | 3381 | 345 | 10.2% | 0.18 (0.16–0.20) | 0.19 (0.16–0.22) |
| Laryngeal | 8283 | 833 | 10.1% | 0.18 (0.17–0.19) | 0.20 (0.18–0.22) |
| Soft tissue sarcoma | 4839 | 635 | 13.1% | 0.24 (0.22–0.26) | 0.26 (0.23–0.29) |
| Rectal | 54 076 | 8177 | 15.1% | 0.29 (0.28–0.29) | 0.30 (0.28–0.31) |
| Hodgkin lymphoma | 4768 | 674 | 14.1% | 0.26 (0.24–0.29) | 0.31 (0.28–0.35) |
| Bladder | 42 234 | 7834 | 18.5% | 0.36 (0.36–0.37) | 0.34 (0.33–0.35) |
| Oesophageal | 32 470 | 7062 | 21.7% | 0.44 (0.43–0.46) | 0.45 (0.43–0.47) |
| CLL | 11 892 | 2950 | 24.8% | 0.53 (0.51–0.55) | 0.53 (0.49–0.56) |
| Renal | 29 469 | 7733 | 26.2% | 0.57 (0.55–0.59) | 0.62 (0.60–0.65) |
| Non-Hodgkin | 46 329 | 12 393 | 26.7% | 0.58 (0.57–0.60) | 0.64 (0.62–0.66) |
| Colon | 97 880 | 30 777 | 31.4% | 0.73 (0.72–0.75) | 0.73 (0.71–0.75) |
| Stomach | 29 893 | 9913 | 33.2% | 0.79 (0.77–0.82) | 0.75 (0.73–0.78) |
| Multiple myeloma | 18 272 | 6693 | 36.6% | 0.93 (0.90–0.96) | 0.96 (0.91–1.00) |
| Mesothelioma | 10 116 | 3631 | 35.9% | 0.90 (0.86–0.93) | 0.96 (0.90–1.02) |
| Lung | 162 543 | 62 498 | 38.5% | Reference | Reference |
| CML | 1702 | 656 | 38.5% | 1.00 (0.91–1.11) | 1.01 (0.88–1.17) |
| Pancreatic | 33 295 | 16 364 | 49.1% | 1.55 (1.51–1.58) | 1.56 (1.51–1.62) |
| Liver | 14 732 | 7270 | 49.3% | 1.56 (1.51–1.61) | 1.60 (1.52–1.68) |
| Unknown primary | 43 290 | 24 805 | 57.3% | 2.15 (2.10–2.19) | 2.00 (1.94–2.07) |
| AML | 9611 | 5388 | 56.1% | 2.04 (1.96–2.13) | 2.15 (2.02–2.29) |
| Small intestine | 3399 | 1863 | 54.8% | 1.94 (1.81–2.08) | 2.15 (1.95–2.38) |
| Brain | 16 710 | 11 175 | 66.9% | 3.23 (3.12–3.34) | 3.96 (3.77–4.17) |
| ALL | 416 | 329 | 79.1% | 6.05 (4.78–7.67) | 7.19 (5.08–10.16) |
Abbreviations: ALL=acute lymphoblastic leukaemia; AML=acute myeloid leukaemia; CI=confidence interval; CLL=chronic lymphocytic leukaemia; CML=chronic myeloid leukaemia; NA=not applicable.
P<0.0001 for all based on joint test of categorical variables. A modest amount of overdispersion was found resulting in an increase in the width of confidence intervals of 45%.
See also Elliss-Brookes .
Figure 1Cancer-specific odds ratios and 95% confidence intervals for emergency presentation comparing ( Note that mesothelioma is not displayed in C, see Figure 2 for details.
Figure 2Cancer-specific odds ratios and 95% confidence intervals for emergency presentation by age group compared with 65–74 years (reference). Note that where cancer-specific age groups contained no cases or all cases were either emergency or non-emergency presentations, odds ratios cannot be estimated and are not shown. This relates to the two younger age groups (25–34 or 35–44), for a total of 30 individual tumours across nine cancers.
Figure 3Predicted risk of diagnosis of cancer through an emergency presentation for men in three age groups (45–54, 65–74 and 85+ years), two deprivation groups (most and least deprived) and with 27 cancers. Confidence intervals can be found in Supplementary Online Material 2.